Fosfestrol

Also known as: Diethylstilboestrol Diphosphate

Drug #327

Fosfestrol is a synthetic non-steroidal estrogen (hormone). Fosfestrol is used in the treatment of prostate cancer.

Primary Characteristics

Fosfestrol is also known as Diethylstilboestrol Diphosphate.

It is of Synthetic origin and belongs to Stilboestrol.

It belongs to Oestrogen Agonist pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent pharmacological group. It is also classified under Sex Hormones .

Molecular Weight: 428.3 · Solubility in Water: > 1 in 100 · Solubility in Alcohol: > 1 in 30 · Non-proprietary name: Fosfestrol.

Pharmacokinetics

Absorption: Fosfestrol has an oral bioavailability is 75% (±5%).

Distribution: Fosfestrol has a plasma protein binding is high.

Elimination: it is metabolised via rapid, renal excretion is major.

Indications

Fosfestrol is primarily indicated in conditions like Adjunct in the treatment of opiod dependence, Breast cancer, Dermatomyositis, Nasopharyngeal fibromas, Oncology, Parathyroid carcinoma, Plasmacytomas, Prostatic cancer, Rheumatoid arthritis.

Contraindications

Fosfestrol is contraindicated in conditions like Hypertension, Cardiac failure, Liver diseases, Cerebrovascular disease.

Dosage

Fosfestrol's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
3.571 mg/kg	3.571 mg/kg	Every 8h	IV	Maintenance, per week
10.713 mg/kg	10.713 mg/kg	Every 24h	IV	Initially for 5 Days or As Required
Paediatric Dosage (20kg)
0 – 0	—	—		Unlikely to be used in this age group
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Fosfestrol in overdosage may give rise to further complications which include Breast enlargement , CHF, Congestive heart failure , Pulmonary embolism , Testicular atrophy , Bone marrow toxicity , Breast tenderness , CVA , Mental disturbances , Pulmonary thrombosis .

Fosfestrol produces potentially life-threatening effects which include Fluid & sodium retention, Thromboembolic cardiovascular accidents. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Fosfestrol are Fluid retension.

Fosfestrol is known to cause more or less tolerable side effects which are usually transient. These include Anorexia , Diarrhea, Dizziness, Fever, Nausea and vomiting, Perineal pain, Perineal pruritis.

Warnings / Precautions

High doses of estrogen used in treatment of malignant disease should be used cautiously in patients with cerebrovascular disorder, cardiovascular disease, coronary artery disease, venous thromboembolism or liver impairment. Estrogens should be used with caution in children, because premature closure of epiphysis may occur resulting in inhibited linear growth and small stature. Slow infusion is not recommended, because cytotoxic concentration of drug is not achieved. It is not recommended for use during pregnancy.

Available Brands

None recorded.

Storage Conditions

Fosfestrol should be stored Tab, Inj.

Drug Classification

1.8.3 — Hormones and antihormones